Sajni Josson-Gururajan

Dr. Josson-Gururajan is an experienced Ph.D. Scientist with expertise in oncology (Tumor Microenvironment), immuno-oncology and in vivo pharmacology. Dr. Josson-Gururajanv worked at Genesis Biotechnology Group on a small molecule drug discovery platform, targeting immuno-oncology pathways. Additionally, Dr. Josson-Gururajan worked at NeoStrata (now J&J), and contributed to the launch of a novel age reverse cream with Micropeptide229. Prior to that, Dr. Josson-Gururajan worked in academia for several years, and published 27 peer reviewed papers and 2 patents in oncology and bone metastasis. Dr. Josson-Gururajan’s completed her postdoctoral training at Emory University, and earned her PhD in Toxicology at the University of Kentucky. In her doctoral work she developed small molecules to target non-canonical NF-kappaB pathway, and studied its role in cancer radiation resistance.